Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Rush

Showing results (271-280 of 292) with videos related to

Pageof 30
Sort By:
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 25, 2019
First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibodyPascal Espié, YanLing He, Phillip Koo, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 18, 2018
Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibodyJacinda Ristov, Pascal Espie, Peter Ulrich, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 2017
Small-molecule inhibitors directly target CARD9 and mimic its protective variant in inflammatory bowel diseaseElizaveta S Leshchiner, Jason S Rush, Michael A Durney, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|November 21, 2023
Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized studyBaltazar GomezMancilla, Matthew N Meriggioli, Angela Genge, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 4, 2015
A novel, blocking, Fc-silent anti-CD40 monoclonal antibody prolongs nonhuman primate renal allograft survival in the absence of B cell depletionF Cordoba, G Wieczorek, M Audet, et al.
Immunity|October 22, 2015
Ubiquitin Ligase TRIM62 Regulates CARD9-Mediated Anti-fungal Immunity and Intestinal InflammationZhifang Cao, Kara L Conway, Robert J Heath, et al.
Science Translational Medicine|September 22, 2021
Drug repurposing: Misconceptions, challenges, and opportunities for academic researchersC Glenn Begley, Mark Ashton, Jonathan Baell, et al.
Bioorganic & Medicinal Chemistry|September 8, 2004
Combinatorial synthesis of substituted 3-(2-indolyl)piperidines and 2-phenyl indoles as inhibitors of ZipA-FtsZ interactionLee D Jennings, Kenneth W Foreman, Thomas S Rush, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2020
Discovery of potent, orally bioavailable in vivo efficacious antagonists of the TLR7/8 pathwayPhil B Alper, Jonathan Deane, Claudia Betschart, et al.
Nature Chemical Biology|April 3, 2019
Discovery of glycerol phosphate modification on streptococcal rhamnose polysaccharidesRebecca J Edgar, Vincent P van Hensbergen, Alessandro Ruda, et al.
Pageof 30

Showing results (271-280 of 292) with videos related to

Sort By:
Pageof 30
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 25, 2019
First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibodyPascal Espié, YanLing He, Phillip Koo, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 18, 2018
Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibodyJacinda Ristov, Pascal Espie, Peter Ulrich, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 2017
Small-molecule inhibitors directly target CARD9 and mimic its protective variant in inflammatory bowel diseaseElizaveta S Leshchiner, Jason S Rush, Michael A Durney, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|November 21, 2023
Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized studyBaltazar GomezMancilla, Matthew N Meriggioli, Angela Genge, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 4, 2015
A novel, blocking, Fc-silent anti-CD40 monoclonal antibody prolongs nonhuman primate renal allograft survival in the absence of B cell depletionF Cordoba, G Wieczorek, M Audet, et al.
Immunity|October 22, 2015
Ubiquitin Ligase TRIM62 Regulates CARD9-Mediated Anti-fungal Immunity and Intestinal InflammationZhifang Cao, Kara L Conway, Robert J Heath, et al.
Science Translational Medicine|September 22, 2021
Drug repurposing: Misconceptions, challenges, and opportunities for academic researchersC Glenn Begley, Mark Ashton, Jonathan Baell, et al.
Bioorganic & Medicinal Chemistry|September 8, 2004
Combinatorial synthesis of substituted 3-(2-indolyl)piperidines and 2-phenyl indoles as inhibitors of ZipA-FtsZ interactionLee D Jennings, Kenneth W Foreman, Thomas S Rush, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2020
Discovery of potent, orally bioavailable in vivo efficacious antagonists of the TLR7/8 pathwayPhil B Alper, Jonathan Deane, Claudia Betschart, et al.
Nature Chemical Biology|April 3, 2019
Discovery of glycerol phosphate modification on streptococcal rhamnose polysaccharidesRebecca J Edgar, Vincent P van Hensbergen, Alessandro Ruda, et al.
Pageof 30